Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IKBKB | O14920 | 11/20 | 0.60 |
| ▸ | CHEK1 | O14757 | 2/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | HTR7 | P34969 | 2/20 | 0.45 |
| ▸ | MAP3K7 | O43318 | 1/20 | 0.43 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.42 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4092564 | 0.95 | IKBKB (0.56) | IKBKBCHEK1ALDH1A1KDM4ESMN1; SMN2 | |
| SCHEMBL1385148 | 0.81 | CHEK1 (0.73) | IKBKBCHEK1MAP3K7 | |
| SCHEMBL1383955 | 0.81 | IKBKB (0.82) | IKBKBCHEK1ALDH1A1KDM4ESMN1; SMN2 | |
| SCHEMBL4092536 | 0.81 | IKBKB (0.71) | IKBKBCHEK1MAP3K7 | |
| SCHEMBL4088491 | 0.80 | MAP3K7 (0.54) | IKBKBCHEK1ALDH1A1KDM4ESMN1; SMN2 | |
| SCHEMBL3886640 | 0.79 | IKBKB (0.51) | IKBKBCHEK1ALDH1A1KDM4ESMN1; SMN2 | |
| SCHEMBL4085764 | 0.79 | MAP3K7 (0.53) | IKBKBCHEK1ALDH1A1KDM4ESMN1; SMN2 | |
| SCHEMBL7481043 | 0.78 | KDM4E (0.54) | IKBKBALDH1A1KDM4EMAP3K7 | |
| SCHEMBL6613050 | 0.76 | IKBKB (0.73) | IKBKBCHEK1ALDH1A1SMN1; SMN2MAP3K7 | |
| SCHEMBL4088607 | 0.76 | CHEK1 (0.74) | IKBKBCHEK1MAP3K7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7358376-B2 | Substituted Thiophene compounds | ASTRAZENECA AB (SE) | 2008-04-15 | — | — | US | claimed |
| EP-1261600-B1 | HETEROAROMATIC CARBOXAMIDE DERIVATIVES AND THEIR USE AS INHIBITORS OF THE ENZYME IKK-2 | ASTRAZENECA AB (SE) | 2004-05-06 | — | — | EP | claimed |
| US-20020107252-A1 | Novel Compounds | ASTRAZENECA AB (SE) | 2002-08-08 | — | — | US | claimed |
| US-20090181962-A1 | Substituted thiophene compounds | ASTRAZENECA AB, A SWEDEN CORPORATION | 2009-07-16 | — | — | US | disclosed |
| US-7358376-B2 | Substituted Thiophene compounds | ASTRAZENECA AB (SE) | 2008-04-15 | — | — | US | disclosed |
| US-20050075341-A1 | Compositions of a cyclooxygenase-2 selective inhibitor and an IKK inhibitor for the treatment of ischemic mediated central nervous system disorders or injury | PHARMACIA CORPORATION (US) | 2005-04-07 | — | — | US | disclosed |
| WO-2005009354-A2 | COMPOSITIONS OF A CYCLOOXYGENASE-2 SELECTIVE INHIBITOR AND AN IKK INHIBITOR FOR THE TREATMENT OF ISCHEMIC-MEDIATED CENTRAL NERVOUS SYSTEM DISORDERS OR INJURY | PHARMACIA CORPORATION (US) | 2005-02-03 | — | — | WO | disclosed |
| EP-1261600-B1 | HETEROAROMATIC CARBOXAMIDE DERIVATIVES AND THEIR USE AS INHIBITORS OF THE ENZYME IKK-2 | ASTRAZENECA AB (SE) | 2004-05-06 | — | — | EP | disclosed |
| EP-1261600-A1 | HETEROAROMATIC CARBOXAMIDE DERIVATIVES AND THEIR USE AS INHIBITORS OF THE ENZYME IKK-2 | AstraZeneca AB (SE) | 2002-12-04 | — | — | EP | disclosed |
| US-20020107252-A1 | Novel Compounds | ASTRAZENECA AB (SE) | 2002-08-08 | — | — | US | disclosed |
| WO-2001058890-A1 | HETEROAROMATIC CARBOXAMIDE DERIVATIVES AND THEIR USE AS INHIBITORS OF THE ENZYME IKK-2 | ASTRAZENECA AB (SE) | 2001-08-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090181962-A1 | Substituted thiophene compounds | ABCG2, SULT1E1, TPMT | IKBKB 3065/4885CHEK1 2784/4885ALDH1A1 165/4885 |
| US-20020107252-A1 | Novel Compounds | UGT1A1, CYP1B1, CYP1A1 | IKBKB 2413/4885CHEK1 3060/4885ALDH1A1 35/4885 |
| US-20050075341-A1 | Compositions of a cyclooxygenase-2 selective inhibitor and an IKK inhibitor for the treatment of ischemic mediated central nervous system disorders or injury | IKBKE, IKBKG, IKBKB | IKBKB 3/4885CHEK1 1097/4885ALDH1A1 3943/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.